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Abstract
Background
Leprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and
preventable disability affecting hands, feet and eyes. Type 1 Reactions are treated with oral
corticosteroids. There is little evidence on alternative treatments for patients who do not
respond to steroids or experience steroid adverse effects. We report the results of a ran-
domized controlled trial testing the efficacy and adverse effect profile of ciclosporin and
prednisolone (CnP) in comparison to prednisolone only (P) in patients with new T1R in Ethi-
opia. Ciclosporin is a potent immunosuppressant. Outcomes were measured using a clini-
cal severity score, recurrence rate, adverse events and quality of life.
Results
Seventy three patients with new T1R were randomized to receive CnP or P for 20 weeks.
Recovery rates in skin signs was similar in both groups (91% vs 88%). Improvements in
nerve function both, new and old, sensory (66% vs 49%) and motor (75% vs 74%) loss
were higher (but not significantly so) in the patients on CnP. Recurrences rates of T1R
(85%) were high in both groups, and recurrences occurred significantly earlier (8 weeks) in
patients CnP, who needed 10%more additional prednisolone. Serious major and minor
adverse events rates were similar in patients in the two treatment arms of the study. Both
groups had a significant improvement in their quality of life after the study, measured by the
SF-36.
Conclusions
This is the first double-blind RCT assessing ciclosporin, in the management of T1R in Africa.
Ciclosporin could be a safe alternative second-line drug for patients with T1R who are not
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improving with prednisolone or are experiencing adverse events related to prednisolone.
This study illustrates the difficulty in switching off leprosy inflammation. Better treatment
agents for leprosy patients with reactions and nerve damage are needed.
Author Summary
Leprosy infection is cured with multi-drug therapy (MDT), but patients may develop
immune mediated skin and nerve lesions. These immunological reactions lead to disability
and deformity secondary to neuropathy. Prednisolone is the main drug used to treat reac-
tions but is only partially effective and patients have a high rate of side effects. Identifying
better agents for treating leprosy reactions is an important clinical goal. We tested the
safety and efficacy of ciclosporin, an immunosuppressant used in many inflammatory
conditions, in Type 1 reactions (T1R) in leprosy patients in Ethiopia. A double-blind ran-
domized controlled clinical trial comparing the efficacy and adverse event profiles of
ciclosporin and prednisolone was conducted in patients presenting with acute T1R.
Patients on ciclosporin and prednisolone had similar improvements in clinical outcomes
which were measured as skin and nerve function improvement. Both groups had a high
rate of T1R recurrence (85%) and the patients on ciclosporin required more additional
prednisolone to treat recurrences. We assessed patient quality of life and this was signifi-
cantly improved with both treatments. This is the first assessment of patient quality of life
in a leprosy patients trial. Ciclosporin may be a useful alternative in the treatment of T1R,
but that the need for additional steroids decreases its value.
Introduction
Leprosy is a chronic granulomatous infection principally affecting the skin and peripheral
nerves caused by the obligate intracellular organismMycobacterium Leprae [1]. In 2014, the
WHO reported 213 899 new cases globally [2]. Multi-drug therapy (MDT) cures the infection
byMycobacterium leprae. Although the bacteria may be eliminated, the damage done to nerves
by the bacteria and by consequent immunological reactions leads to very visible and stigmatiz-
ing disabilities and deformities.
Type 1 reactions (T1R) affect up to 30% of patients with borderline leprosy [3]. Although
T1Rs can occur at any time, the frequency is higher in the first six months of MDT treatment
[4]. T1R manifest clinically with erythema and oedema of skin lesions and tender peripheral
nerves with loss of nerve function. Skin lesions become acutely inflamed and oedematous.
Inflammation is usually in pre-existing lesions, but not all the lesions may be involved. Oedema
of the hands, feet and face can also be a feature of a reaction but systemic symptoms are
unusual. Nerves can become swollen, painful and tender. Acute neuritis may also occur with-
out evidence of skin inflammation. The inflammatory process in leprosy reactions leads to
nerve function impairment (NFI) which if not treated rapidly leads to permanent loss of nerve
function causing peripheral sensory and motor neuropathy. Recurrent T1Rs can lead to further
nerve damage [5]. Progressive NFI can also occur in the absence of a reactional state, so the his-
tory of timing of symptoms aids to differentiate from NFI due to a reaction.
T1Rs are the result of spontaneous enhancement of cellular immunity and delayed hyper-
sensitivity reactions toM.leprae antigens presented by macrophages and dendritic cells in the
skin and by Schwann cells on nerves [6,7]. Immuno-suppression is required to control the
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placebo tablets were purchased from Panacea–
Biotec (India) and E-Pharm (Ethiopia), both
companies with GMP certification.
symptoms and signs of T1R, but this management remains challenging. Oral prednisolone, the
drug of choice, has frequent side effects and approximately 40% of individuals with T1R do not
show clinical improvement [8,9]. There is a lack of evidence for efficacious and safe second line
treatments for T1R.
Ciclosporin is a potent immuno-suppressant that has been widely and successfully used as a
treatment for psoriasis, Behcet’s disease, rheumatoid arthritis, inflammatory bowel disease and
transplantation. Given that ciclosporin selectively inhibits the activation of CD4 T cells and the
expression of cytokines such as IL-2 and TNF-α [10], it was thought to be useful in the treat-
ment of T1R. Three case studies have been published [11,12], showing good response to ciclos-
porin and delayed recurrence of T1R. An uncontrolled pilot study was carried out assessing the
efficacy of ciclosporin in severe T1R in Ethiopian and Nepali patients [13]. In the Ethiopian
part of the study, performed in ALERT Hospital, Addis Ababa, ciclosporin was given to 33
patients with T1R for three months in a dose range of 5–7.5mg/kg/day. This led to improve-
ments in skin lesions in 85% of patients and 45% of patients had improvement in nerve pain
and tenderness. Sensory nerve impairment improved in 45% of Ethiopian patients and motor
function impairment in 53% of patients. Almost 88% of Ethiopian patients needed the higher
dose of ciclosporin to show improvement partly because of the severity of the reaction. The
study showed that in those patients treated with high-dose ciclosporin, 53% of patients with
sensory impairment and 60% with motor impairment improved. A few Ethiopian patients with
NFI of greater than 6 months duration, responded to ciclosporin. This was an encouraging
result as in many leprosy endemic countries patients present late with chronic NFI. Almost
70% percent of Ethiopian patients developed new signs of reaction after stopping treatment,
suggesting that they would benefit from a treatment period longer than three months. In the
Nepali study, ten patients treated with ciclosporin were compared to a similar group of patients
treated with prednisolone. Improvement in skin lesion was at 87.5% in the ciclosporin group
compared to 74% in the prednisolone group. Similarly the ciclosporin group showed 83%
improvement in sensory testing compared to 22% in the prednisolone group.
Few ciclosporin side effects were seen in the two clinical trials conducted in T1R. Of the 33
Ethiopian patients, three developed hypertension; of the ten Nepali patients one developed
jaundice (possibly dapsone related), two developed raised serum creatinine levels and two
other patients developed mild side effects (loss of appetite and indigestion controlled with
antacids).
The results of the above studies were encouraging as it appeared that ciclosporin monother-
apy may be an effective alternative treatment in prednisolone-resistant or prednisolone-depen-
dent cases of T1R. The study recommended using higher doses of ciclosporin (7.5mg/kg/day)
in future studies, longer periods of treatment, as well as tapering the drug slowly or adding low
dose prednisolone to prevent relapse.
We tested our hypothesis that ciclosporin would be as effective as prednisolone in the treat-
ment of patients with leprosy reactions and nerve function impairment and that patients
treated with ciclosporin would have fewer side effects than patients treated with prednisolone.
A randomized controlled trial comparing ciclosporin and prednisolone in the treatment of lep-
rosy T1R was designed and conducted.
Methods
Study design and participants
A double-blind controlled trial was conducted randomizing patients with new and recent onset
T1R to treatment with either ciclosporin and prednisolone or prednisolone alone. Patients
were recruited at the ALERT hospital leprosy clinic, in Addis Ababa, Ethiopia.
RCT: Ciclosporin versus Prednisolone for Leprosy Type 1 Reaction
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Case definitions
Type 1 Reaction (T1R) was diagnosed when a patient with leprosy had erythema and oedema
in skin lesions and/or neuritis. A patient could have skin reaction only, a nerve reaction only or
a skin and nerve reaction.
Neuritis was diagnosed when a leprosy patient had any of the following on history or
examination:
• Spontaneous nerve pain, paraesthesia or nerve tenderness
• New sensory or motor impairment of recent onset
• Mixed sensory and/or motor impairment with nerve tenderness.
Nerve function impairment (NFI) was defined as clinically detectable impairment of sen-
sory or motor nerve function using the definitions below [14].
New NFI was defined as less than six months duration of reduction in sensory or motor
function on history or examination.
Motor loss was defined by a decrease in voluntary muscle testing (VMT) score, by 1 point
or more from the normal score of 5, using the modified MRC scale.
Sensory loss was defined by a decrease in sensation as measured by Semmes Weinstein
monofilament testing. In the hands, this was defined as not being able to perceive the 0.2gm
monofilament at 2 points out of 3 in each nerve of the hand. In the feet, this was defined as not
being able to perceive the 2gm monofilament at 3 out of 4 sites of the foot.
Silent neuropathy (SN): A patient had silent neuropathy when he/she had sensory and/or
motor impairment of recent onset (less than six months duration) in an area innervated by one
or more nerve without signs of a reaction (RR or ENL) or nerve pain with or without
tenderness.
T1R recurrence or flare-up was defined as an increase in skin severity score to 4 or more
out of 9 AND/OR an increase in NFI defined as worsening of VMT by one point in two or
more muscles, or by 2 points in one muscle and/or worsening of ST: decreased sensation in at
least two out of 3 points per nerve on the hand and/or 3 or more points on the feet. NB: nerve
tenderness was not part of the definition for T1R recurrence.
NFI outcomes were defined clinically as (based on Marlowe study [13]:
1. Recovered when the motor or sensory function returned to normal;
2. Improved when the motor function improved by the VMT improving by one point in two
or more muscles or by 2 points in one muscle and /or the sensory function improved by at
least two out of 3 points per nerve on the hand and/or 3 or more points on the feet;
3. Not improved when no changes where recorded in either VMT or ST;
4. Worse when the motor function or sensory function where found to be decreased by any
point on VMT and/or ST;
5. Remained stable after treatment when the final assessment at week 28 or 32 showed that
motor and or sensory function was similar or better compared to the end of treatment
assessment at week 20;
6. Relapsed after treatment when the final assessment at week 28 or 32 showed that motor
and or sensory function was worse compared to the end of treatment assessment at week 20.
Clinical Severity Score: used to assess T1R severity (21 items; range of 0–63). The maxi-
mum score possible for skin (A), sensation (B) and motor function (C) are 9, 24 and 30
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respectively. Mild T1R is characterised by a score of 4 or less; moderate T1R by a score between
4.5 and 8.5 and severe T1R is a score of 9 or more. This Severity Scale for T1R based, on the
INFIR clinical severity scoring system, was developed and prospectively validated in Bangla-
desh and Brazil [15]. It has so far been used in clinical trials on intravenous methylpredniso-
lone [16], on azathioprine [17] and in the on-going TENLEP studies [18].
Eligibility
Participants (aged between 18 and 65 years and weighing more than 30 kg) were recruited
from the leprosy clinic in ALERT Hospital, Addis Ababa, Ethiopia. Individuals with newly
diagnosed T1R or neuritis were eligible for entry in the trial.
Exclusion criteria
The following individuals were excluded: those unwilling to give consent or return for follow
up; those with severe active infections such as tuberculosis or severe inter-current disease; HIV
positive individuals; pregnant or breastfeeding women. Women of reproductive age not willing
to use contraception for the duration of the study were also excluded.
Treatment arms
The participants were randomly allocated to receive the standard ALERT hospital prednisolone
regimen for T1R or the ciclosporin (Cn) arm (Table 1). We theorized that given the slow onset
of action of ciclosporin compared to prednisolone and high relapse rate of T1R, the most effec-
tive regimen in leprosy reaction would be an initial ciclosporin dose of 7.5mg/kg/day, divided
in two doses, gradually tapered down over a total period of 20 weeks and adding prednisolone
cover for the first four weeks of treatment. The TIR patients on the prednisolone arm (P)
would get 20 weeks of a gradually reducing course of prednisolone only.
Weight adjusted medication cards for each treatment arm were designed for the pharmacist,
using a 10 kilogram range in patient weight. A double placebo system was used because of the
different formulation of prednisolone (pink tablets) and ciclosporin (brown capsules). Each
placebo was identical to its active counterpart and each participant took a combination of
brown capsules and pink tablets as an essential way of blinding both patients and study
Table 1. Treatment regimen for T1R trial.
Prednisolone alone arm Ciclosporin and Prednisolone arm
Week 1 Prednisolone 40mg+ PC* Ciclosporin 7.5mg/kg + Prednisolone 40mg
Week 2 Prednisolone 40mg + PC Ciclosporin 7.5mg/kg + Prednisolone 40mg
Week 3 Prednisolone 35mg + PC Ciclosporin 7.5mg/kg + Prednisolone 20mg
Week 4 Prednisolone 35mg + PC Ciclosporin 7.5mg/kg + Prednisolone 10mg
Wk 5 & 6 Prednisolone 30mg + PC Ciclosporin 7.5mg/kg + PP**
Wk 7 & 8 Prednisolone 25mg + PC Ciclosporin 7.5mg/kg + PP
Wk 9–12 Prednisolone 20mg + PC Ciclosporin 7.5mg/kg + PP
Wk13–16 Prednisolone 15mg + PC Ciclosporin 6mg/kg + PP
Wk17–18 Prednisolone 10mg + PC Ciclosporin 4mg/kg + PP
Wk19–20 Prednisolone 5mg + PC Ciclosporin 2mg/kg + PP
Total prednisolone 3080mg 770mg
*PC = placebo ciclosporin
**PP = placebo prednisolone
doi:10.1371/journal.pntd.0004502.t001
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physicians. Prednisolone tablets and prednisolone placebo (PP) tablets were produced by Ethi-
opian Pharmaceuticals Manufacturing Factory (EPHARM), in Addis Ababa, Ethiopia. Both
were analysed for active ingredient by Dr Harparkash Kaur at LSHTM. Ciclosporin capsules
(Panimune Bioral) and ciclosporin placebo (PC) capsules were produced by Panacea-Biotec
Ltd, Solan, India and were provided with a certificate of analysis.
Clinical assessments
A full history was taken and clinical examination performed. Nerve function was assessed at
each visit, by one of three trained physiotherapists. Sensory testing was performed with five
Semmes-Weinstein monofilaments at designated test sites on hands and feet. Voluntary mus-
cle power was graded using the modified Medical Research Council scale. The results of the
examination findings were recorded and a Clinical Severity Score calculated using the severity
scale. Severity of reaction was also recorded as mild, moderate or severe by a second physician’s
opinion blinded to the Clinical Severity Score.
Laboratory investigations consisted of the following: slit skin smears for bacterial index, full
blood count, HIV test, renal function, liver function tests, glucose, erythrocyte sedimentation
rate (ESR), urinalysis and a stool specimen examined for ova, cysts and parasites. A skin biopsy
was performed for Ridley-Jopling classification. Symptomatic screening for TB was carried out
by chest x-ray and sputum samples for acid fast bacilli as necessary.
All individuals received three days of albendazole 400mg daily to reduce the risk of hyper-
infection with Strongyloides stercoralis at enrolment.
Women of reproductive age were tested for pregnancy and contraception was prescribed,
usually the oral contraceptive pill and condoms.
Assessments were carried out at weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, and 32 from enrolment.
Assessment consisted of focussed questions about specific symptoms and adverse effects. The
clinical examination including weight and blood pressure was repeated. Blood tests (full blood
count, renal function and liver function), and urinalysis were carried out at each visit.
Quality of life was assessed with a validated Amharic translation of the SF-36 health-related
quality of life assessment tool [19] at recruitment and at week 28. Each patient’s quality of life
is graded with two scores: a physical score (PCS) and a mental score (MCS), which in turn are
composed of four subscales each.
Outcome measures
The primary outcome measure was the change in Clinical Severity Score and in clinical nerve
function impairment and at week 4, 20, and 28 for patients in each treatment arm. Secondary
outcomes were:
1. Mean time to recurrence of T1R for patients in each treatment arm
2. Number of T1R recurrence episodes per patient in each treatment arm:
a. Whilst on treatment (week 1–20)
b. During follow-up (week 21–32)
3. Severity of T1R recurrence for patients in each treatment arm:
a. Whilst on treatment (week 1–20)
b. During follow-up (week 21–32)
4. Amount of extra prednisolone for patients in each treatment arm:
RCT: Ciclosporin versus Prednisolone for Leprosy Type 1 Reaction
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a. Whilst on treatment (week 1–20)
b. During follow-up (week 21–32)
c. Total
5. Frequency of adverse events in patients in each treatment arm
6. Difference in score in Quality of Life assessment between start and end of treatment for
patients in each treatment arm
Criteria for using additional prednisolone were defined as sustained deterioration in nerve
function nerve pain unresponsive to analgesics for a period of at least two weeks; new erythem-
atous and raised skin patches; deterioration in nerve function which the study doctors believe
requires immediate additional prednisolone and ENL flare-up with the appearance of new sub-
cutaneous nodules.
As the study was double-blinded, regimen for additional prednisolone depended on the
time at which the reaction flare-up occurred. If the reaction recurrence was within the first ten
weeks of treatment or there was facial involvement, extra prednisolone was added to make up a
total of 40mg (with the pharmacist deciding on the exact additional dose of prednisolone
required) and then tapered according to the original regimen. If T1R recurrence was after the
first ten weeks of treatment, then prednisolone 20mg was added and tapered down according
to the original regimen. The physician could prescribe more additional prednisolone if the
reaction was severe.
Adverse events were enquired about at each visit using a standardized form with anticipated
adverse events attributable to prednisolone and ciclosporin. Any other adverse events reported
by the participant or identified by the physicians were also recorded. Major adverse events
were defined as any event leading to admission or prolonged admission, study un-blinding or
death. Amongst these were included psychosis, severe infection including tuberculosis, peptic
ulcer, glaucoma, cataract, diabetes mellitus, severe hypertension and haematological abnormal-
ities. Minor adverse events were defined as moon face, acne, hirsutism, gum hyperplasia, fungal
infections, gastric pain requiring antacids or any other minor adverse event not requiring
admission to hospital or un-blinding. Patients who experienced blurred vision were referred to
the ophthalmologist for ophthalmic review and had their serum glucose checked. Three study
physicians (blinded to each other’s decision) reviewed each adverse event and decided whether
it was linked to prednisolone or ciclosporin. Adverse events were also graded by severity, using
the Common Terminology Criteria for Adverse Events [20] grading system.
Randomisation and masking
Eligible individuals were recruited consecutively and randomly assigned in 1:1 ratio (block size of
four), with a computer-generated randomisation list, to one of the two treatment arms. A stan-
dard envelope system was used for allocation concealment. The envelopes were prepared by an
individual who had no other involvement in the study. The allocation procedure was done by the
pharmacist who had no clinic contact and was the only individual aware of the treatment alloca-
tion. All study participants, physicians, nurses, ward staff, laboratory staff and the physiotherapists
were blinded to the allocation. The allocation code was revealed to the researchers once the study
was completed, except in the case of a serious adverse event necessitating un-blinding.
Statistical analysis
The sample size, based on the Hypothesis of Non-Inferiority, was calculated with the study
statistician, in consultation with ALERT hospital physicians. Prednisolone is known to show
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an improvement of 60% in nerve function in new T1R. Given that the true mean cure rates of
the treatment agents and the active control are θ1 = θ2 = 60%, the non-inferiority margin was
selected to be δ = 0.25. The sample size was calculated using a power of β = 80% and signifi-
cance of α = 0.05, giving us a sample of n = 48 in each arm respectively.
The data was entered in Access database and analysed using the Statistical Package for the
Social Sciences (SPSS version 20. SPSS Inc., Chicago, Illinois). An intention to treat analysis
(ITT) was used for calculating the effects of treatment on individuals in each group and t tests
and ANOVA (analysis of variance) were used as appropriate. The Mann-Whitney U test was
used for all statistical tests of continuous variables and Fisher’s exact test was used to compare
dichotomous variables.
Ethics statement
The studies were performed according to the Helsinki Declaration (2008 revision) and
approved by the Ethics Committee of the London School of Hygiene and Tropical Medicine
(5376), the ALERT and AHRI Ethical Review Committee (AA/ht/248/09), the National Ethics
Review Committee of Ethiopia (RDHE/34-90/2009), and the Drug Administration and Con-
trol Authority of Ethiopia (02/12/70/926). All staff involved underwent Good Clinical Practice
training and an independent Data and Safety Monitoring Board reviewed the study design and
the safety and efficacy data. The study is registered with ClinicalTrials.gov: NCT00919815.
Written informed consent was obtained in Amharic or if the patient spoke a different Ethio-
pian language, then the information and consent forms were translated verbally into the appro-
priate language before signing the consent form.
Results
Seventy three patients with recent onset T1R were enrolled into the trial between 12th August
2011 and 25th December 2012. The final assessment was completed on 24th July 2013. Thirty five
individuals were randomized to the ciclosporin arm, and 38 to the prednisolone arm. The partici-
pant flow is shown in the CONSORT flow diagram (Fig 1). The trial was terminated before full
recruitment numbers were reached because of slower recruitment rates than anticipated.
Six patients did not complete the intervention medication. Three patients in the predniso-
lone arm did not attend for review at week 2 or 4. One other patient in the prednisolone arm
had a serious adverse event which led to un-blinding at week 6. He was removed from the
study at his request and continued to take prednisolone at a different facility. Two patients in
the ciclosporin arm were discontinued from the study, one for non-adherence at week 12, and
the second patient had a serious adverse event on week 6 which necessitated un-blinding and
discontinuation of ciclosporin. He continued the study on prednisolone.
The two groups of patients with T1R were not significantly different with respect to sex, age,
Ridley-Jopling classification, or treatment with MDT (Table 2).
Of the 73 participants, 50 had BT leprosy (70% had a negative BI) and 12 patients had BL lep-
rosy. Of all participants presenting with T1R, 64% were newly diagnosed with leprosy. In these
patients the signs and symptoms of the reaction were the reason for seeking medical assistance.
Reaction type
The two groups did not differ significantly in respect of reaction type, or mean number of
enlarged and tender nerves per patient (Table 3). There was a significant difference in the dura-
tion of NFI between patients recruited to the two groups (Chi Square, p = 0.039). Twice as
many patients in the ciclosporin arm reported isolated new NFI but in the prednisolone arm,
there were more patients reporting combination of old and new NFI.
RCT: Ciclosporin versus Prednisolone for Leprosy Type 1 Reaction
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Duration and severity of T1R
Patients in the two treatment arms had similar duration of reported T1R symptoms prior to
presenting at the clinic (p = 0.2). Severity of T1R, assessed both by specialist opinion and by
the Clinical Severity Score, was not significantly different between the two groups (Table 4).
Nerve involvement
The 73 patients recruited had a total of 876 peripheral nerves examined. Nerve function
impairment of less than 6 months duration (new NFI) was reported for 308 nerves (35%). A
Fig 1. CONSORT flow diagram.
doi:10.1371/journal.pntd.0004502.g001
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further 24% of nerves were reported to have been impaired for longer than 6 months (old
NFI). In both old and new NFI, sensory loss was more frequent than motor loss or mixed loss.
Of the nerves examined, 72% were enlarged, and 34% of nerves were tender on palpation. A
Table 2. Description of study participants in each arm.
Participants with new T1R Ciclosporin (n = 35) Prednisolone (n = 38)
Sex Women: men 7:28 8:30
Median age (years) 27 34
Median weight (kg) 52 54
Clinical Ridley- Jopling TT 0 1
classiﬁcation BT 27 23
BB 2 6
BL 5 7
LL 0 1
PNL 1 0
Mean BI* at diagnosis 0.7 0.9
at recruitment 0.2 0.1
MDT status Started at enrolment 25 22
Current 4 7
Completed 6 9
Co-morbidities 2 foot ulcer 1 Foot ulcer
3 skin ulcer
2 skin ulcers
2 fungal infections
2 conjunctivitis
1 intrahepatic cholecystiasis
EHF score (mean) 3.94 3.84
*Mean BI = group mean of each patient’s mean BI
PNL = pure neural leprosy
doi:10.1371/journal.pntd.0004502.t002
Table 3. Reaction type and nerve involvement in study participants.
Participants with new T1R Ciclosporin Prednisolone P value
(n = 35) (n = 38)
Reaction type Skin only 4 8 0.541
Skin and nerves 28 27
Nerve only 3 3
Facial patches 29 25 0.164
Peripheral Oedema 30 28 0.414
Reported NFI at baseline None 3 9 0.039
New 20 10
Old 4 4
Mixed old and new 8 15
Mean number of enlarged nerves per patient 9 8.5 0.306
Mean number of tender nerves per patient 4.7 3.6 0.168
Type 1 reaction occurring in both skin and nerves was present in 76% of participants, whilst 16% had reaction affecting skin only and 8% nerves only.
74% of patients had inﬂamed facial patches and 80% had peripheral oedema on examination.
doi:10.1371/journal.pntd.0004502.t003
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larger proportion of nerves were impaired in the ciclosporin group patients (68% vs. 52%) and
this group had significantly higher proportion of purely sensory and mixed sensory/motor
types of new NFI (p = 0.0387)
The ulnar nerves were found to be both the most frequently enlarged and tender nerves, fol-
lowed by the lateral popliteal, radial cutaneous and posterior tibial nerves. Nerve tenderness
was present in 300 nerves and was more common in the ciclosporin group (40% vs. 29%).
Apart from a higher number of affected sensory nerves in the ciclosporin group, there was no
major significant difference between the two groups of patients with newly diagnosed T1R,
recruited to the study.
Primary outcome: Change in Clinical Severity Score and in clinical nerve
function impairment
The change in group mean Clinical Severity Score over time for patients in each arm of the
trial is shown in Fig 2. Changes in the three sub-scores are also shown. Variation in group
mean T1R severity scores during the 32 weeks and between the two treatment arms, was
assessed by ANOVA. Patients in both treatment arms had large and statistically significant
improvement with time in all four scores (p<0.000). This is consistent with a good clinical
response with both treatments.
There was no significant difference in all four severity scores between the two treatment
arms over the 32 weeks (Score A, p = 0.241; Score B, p = 0.664, Score C, p = 0.749 and Clinical
Severity Score, p = 0.531).
In the ANOVA week by week breakdown, patients on the ciclosporin arm showed signifi-
cantly higher skin score (A), at weeks 6 and 8 (p<0.000). This was probably due to a greater
number of patients in the ciclosporin arm experiencing a flare-up in skin reaction at this time.
The difference between the two treatment groups in median improvement of Clinical Sever-
ity Scores were compared at week 0, 4, 6, 20, and 28 as shown in Fig 3. These time periods were
deemed important, as at week 4, the prednisolone in the ciclosporin arm is stopped; at week 6
is the steroid free period for those on the ciclosporin arm; at week 20 the intervention period
ends, and week 28 represents the end of the study.
All four components of the severity scores show a downward trend, suggesting improve-
ment in both groups of patients. The largest and sustained decrease in score occurs in the skin
(A). At week 6, the difference in skin score between the two treatment arms is evident with the
patients in the ciclosporin arm having a wider range in score despite a similar median score.
Throughout the 32 weeks in the study, the median sensory score (B) does not reach the score
of 0, which represents intact sensation.
Table 4. Duration and severity of T1R in study participants.
Participants with new T1R Ciclosporin Prednisolone P value
(n = 35) (n = 38)
Reported mean duration of T1R symptoms (days) 61.5 (6–180: median 58) 49.6 (5–150: median 44) 0.2
Severity by specialist opinion Moderate 1 3 0.667
Severe 34 35
Severity by Clinical Severity Score (mean) Score A (skin) 5.74 5.11 0.19
Score B (sensation) 8.53 7.77 0.53
Score C (motor) 9.37 6.92 0.58
Total CSS score 22.96 19.79 0.36
doi:10.1371/journal.pntd.0004502.t004
RCT: Ciclosporin versus Prednisolone for Leprosy Type 1 Reaction
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004502 April 5, 2016 11 / 29
Analysis by patient and by nerves were also done to assess the improvement in T1R in
patients treated with either ciclosporin or prednisolone.
The general outcome for patients (Table 5) was decided by study physician assessment on
review of patient notes and taking into account the changes in skin as well as nerves between week
0 and week 20, the end of the intervention period. There is no significant difference in all six clinical
outcomes listed in Table 5 between the patients in the two treatment arms. Clinical outcomes in
the follow-up period were recorded as those that maintained improvement and those that relapsed
at the end of treatment. A larger proportion of patients appears to be maintaining improvement
after the end of the intervention period in the ciclosporin arm (67% vs.39%, p = 0.044).
The change in motor function, between baseline and the end of intervention, in nerves with
reported weakness of less than six months duration is not significantly different between the
two study arms (p = 0.085). Fig 4 illustrates that motor function in both treatment arms recov-
ered or improved in a large proportion of nerves (74% in the ciclosporin arm and 68% in the
prednisolone arm (one tailed t test: p = 0.043).
70% of nerves with sensory loss reported as being of less than six months duration in the
ciclosporin arm and 56% in the prednisolone arm improved or recovered (Fig 5). Patients who
received ciclosporin and prednisolone had better improvement in nerve function impairment
than those who received prednisolone only (one tailed t test: p = 0.038).
Patients in both treatment arms had their nerves assessed three months after the end of the
intervention and improvement in nerve function was maintained in the majority of patients.
Motor function remained stable in 88% (Cn arm) and 76% (P arm), and sensory function in
78% (Cn arm) and 79% (P arm).
Fig 2. Groupmean and standard error in Clinical Severity Scores with time by treatment arm. Score A (skin), Score B (sensation) and Score C (motor).
(0 marks the area in Score A where the difference between the treatment arms is significant).
doi:10.1371/journal.pntd.0004502.g002
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Nerves reported to have been impaired for longer than six months also showed improve-
ment. Of the nerves with old motor function 37% in the Cn arm and 39% in the P arm recov-
ered or improved. Of the nerves with old loss of sensation, 46% in the Cn arm and 36% in the P
arm recovered or improved.
Secondary outcomes
Mean time to recurrence of T1R. Fifty nine out of 69 (85%) patients recruited with new
T1R had a T1R recurrence.
Of the 73 patients recruited to the study, the three who withdrew from the prednisolone
arm early in the study, and one patient in the prednisolone arm who then had ENL recurrences
only throughout the 32 weeks in the study have been removed from this analysis. Ten patients
had no T1R recurrence during the 32 weeks in the study: five patients in the ciclosporin arm
Fig 3. Median and inter-quartile ranges in Clinical Severity Scores.
doi:10.1371/journal.pntd.0004502.g003
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and five in the prednisolone arm. Six patients, two in the ciclosporin arm and four in the pred-
nisolone arm, had an ENL episode, in the 32 weeks in the study. These patients experienced
both ENL and T1R, and so have been retained in the analysis.
The cumulative probability of T1R recurrence at a given point of time is shown on a
Kaplan-Meier survival curve and there is no statistically significant difference between the two
treatment arms (Log Rank- Mantel Cox, p = 0.157) (Fig 6).
Table 5. Clinical outcome in patients with new T1R.
Clinical outcome in patients Ciclosporin Prednisolone P value
Number of patients enrolled 35 38
General T1R status
No (%) recovered 1 3% 4 11% 0.254
No (%) improved 31 89% 26 75%
No (%) not improved 3 8% 5 14%
No (%) maintained improvement after Rx 22 67% 12 39% 0.044
No (%) relapsed after Rx 11 33% 19 61%
Skin signs
No (%) recovered 32 91% 31 88% 0.33
No (%) improved 3 9% 2 6%
No (%) no change 0 0 2 6%
No (%) maintained improvement after Rx 28 85% 21 68% 0.143
No (%) relapsed after Rx 5 15% 10 32%
Sensation
No (%) recovered 1 3% 0 0 0.204
No (%) improved 22 63% 17 49%
No (%) no change (normal) 5 14% 12 34%
No (%) not improved 7 20% 6 17%
No (%) maintained improvement after Rx 26 79% 23 74% 0.771
No (%) relapsed after Rx 7 21% 8 26%
Motor function
No (%) recovered 16 46% 14 40% 0.957
No (%) improved 10 29% 12 34%
No (%) no change (normal) 6 17% 6 17%
No (%) not improved 3 8% 3 8%
No (%) maintained improvement after Rx 27 82% 29 94% 0.259
No (%) relapsed after Rx 6 18% 2 6%
Nerve tenderness
No (%) improved 25 71% 22 63% 0.285
No (%) no change (normal) 7 20% 12 34%
No (%) not improved 3 9% 1 3%
No (%) maintained improvement after Rx 28 85% 23 74% 0.359
No (%) relapsed after Rx 5 15% 8 26%
EHF Disability Score
No (%) improved 23 66% 18 51% 0.168
No (%) no change (normal) 9 26% 16 46%
No (%) worse 3 8% 1 3%
T test done with Chi Square
doi:10.1371/journal.pntd.0004502.t005
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The mean time to first episode of T1R recurrence was 8.7 weeks (median = 8) in the ciclos-
porin group and 15.2 (median = 16) weeks in the prednisolone group. The earlier time to first
recurrence in the patients on the ciclosporin arm was statistically significant (Mann-Whitney
U Test, p = 0.0058).
Fig 7 shows a cluster of T1R recurrence events around week 6 and week 8 in the ciclosporin
arm patients. The analysis of Clinical Severity Score showed that at weeks 6 and 8, there was a
statistical significant difference between the two treatment arms on the skin related A score.
Prednisolone was given for the first four weeks of the study to patients on the ciclosporin arm
to cover for the slow onset of action of ciclosporin. At week 4 prednisolone is stopped in these
patients and many of them are having a flare-up of T1R at weeks 6 and 8, in particular in the
skin signs of T1R, as shown on Fig 2.
Number of T1R recurrence episodes. The mean number of recurrence per patient was
1.35 (median 1) for the patients in the ciclosporin arm and 1.49 (median 1) for the patients in
the prednisolone arm. There was no statistically significant difference between the two arms
(Mann-Whitney U Test p = 0.365).
A total of 93 episodes of T1R recurrence were experienced by the 59 patients. The largest
difference in numbers of T1R recurrences occurs during the intervention period, with patients
in the ciclosporin group experiencing 13 more recurrences than those in the prednisolone
group (Fig 8). The difference in numbers of T1R recurrences within the intervention period or
the follow-up period were not statistically significant.
Fig 4. Motor function change in nerves with newweakness.
doi:10.1371/journal.pntd.0004502.g004
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Severity of T1R. The severity of the 93 episodes of T1R recurrence was graded using the Clin-
ical Severity Score (Fig 9). In both intervention and follow-up periods, there was no statistically sig-
nificant difference in the distribution of severity of recurrences between the two treatment arms,
when graded by the Clinical Severity Score (Chi Square p = 0.926 and p = 0.162 respectively).
Amount of extra prednisolone. Table 6. shows the summary data for mean additional
and total prednisolone received by all the patients recruited, per treatment arm.
Patients in the ciclosporin arm received significantly more additional prednisolone during the
intervention period (p<0.000) and in the total study period (p = 0.002). Patients in the ciclosporin
arm received 10% less steroid (mean 758mg) in total than the patients in the prednisolone arm.
Sixty patients in total received additional prednisolone during the study. Additional pred-
nisolone was given for 91 T1R occurrences, as defined in the study protocol, and two for iso-
lated nerve tenderness (Table 7). Twelve ENL episodes occurred in six patients during the
study. Ten patients, five in each study arm did not require additional prednisolone.
Excluding the patients with ENL does not alter the statistically significant differences seen
in Table 6., in terms of additional prednisolone prescribed to each group.
Further sub-analysis showed that patients in the ciclosporin arm have more episodes of
reaction recurrences requiring additional prednisolone. Severe recurrences involving skin
flare-up are more frequent (16 vs 8) and occur more frequently in weeks 4 to 8 of the study.
An ANOVA was conducted to get a clearer impression on the difference of mean predniso-
lone required by patients in both treatment arms throughout the different weeks in the study
(Fig 10).
Fig 5. Sensory function change in nerves with new loss of sensation.
doi:10.1371/journal.pntd.0004502.g005
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There was a significant difference (p = 0.003) in mean weekly prednisolone dose in both
arms with time as less prednisolone was required by both groups as the study progressed. The
week by week ANOVA breakdown shows the following important points:
• Weeks 4–15: significantly more prednisolone is taken by patients in the prednisolone arm
• Week 6: a sharp increase in prednisolone taken by patients on the ciclosporin arm is noted
• Week 20–24: significantly more prednisolone is taken by patients in the ciclosporin arm
• Week 24: an increase in the requirement of prednisolone is seen in patients on the predniso-
lone arm as flare-ups start to occur once the prednisolone regimen is stopped
• Week 29–32: at the end of the follow-up period, patients from the ciclosporin arm are on less
prednisolone although this difference was not found to be statistically significant.
Adverse events. All the patients recruited to the trial experienced at least one adverse
event during their period in the study. Patients experiencing minor and/or major adverse
events that may be attributed to the study drugs are shown in Table 8. Patients are listed
Fig 6. Survival curve for patients without a T1R recurrence.
doi:10.1371/journal.pntd.0004502.g006
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according to the study arm they were assigned to regardless of any additional prednisolone
received during the study period to control any recurrence in reaction symptoms.
Fig 7. Time of first recurrence of T1R after initial control.
doi:10.1371/journal.pntd.0004502.g007
Fig 8. Number of T1R recurrence episodes per treatment arm.
doi:10.1371/journal.pntd.0004502.g008
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In this study, as patients in the ciclosporin arm receive 4 weeks of prednisolone at the start
of the study, and further prednisolone for any flare-ups of reaction, it is misleading too associ-
ate the adverse event entirely with ciclosporin.
To address this and refine possible causative links, the adverse events association with either
prednisolone or ciclosporin, were revised. Some adverse events are clearly related to one drug
only, for example moon face and prednisolone, or gum hyperplasia and ciclosporin. Other
adverse events can be caused by either of the two drugs. When the adverse event occurred after
the end of ciclosporin treatment (week 21), it was attributed to prednisolone if the patient was
on additional prednisolone. Adverse events occurring, in the ciclosporin arm, at a time when
patients were receiving high doses of additional prednisolone were attributed to prednisolone.
Fig 9. Number of T1R recurrence episodes by Clinical Severity Score.
doi:10.1371/journal.pntd.0004502.g009
Table 6. Additional and total prednisolone received in patients. (Group mean, range and median in mg.)
Period in study Ciclosporin arm Prednisolone arm Whole group (n = 73) P value (Mann Whitney U
(n = 35) (n = 38) test)
INTERVENTION 1608 559 1062 <0.000
PERIOD (0–5705) 1400 (0–2030) 0 (0–5705) 840
FOLLOW-UP PERIOD 1067 799 927 0.208
(0–2870) 1260 (0–2310) 623 (0–2870) 980
TOTAL STUDY PERIOD 2680 1358 1992 0.002
(0–8085) 2520 (0–3710) 1435 (0–8085) 1820
TOTAL PREDNISOLONE 3450 4208 3845 0.031
(770–8855) 3290 (3010–6160) 4445 (560–8855)
doi:10.1371/journal.pntd.0004502.t006
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Any equivocal adverse events that can be related to both drugs were separated out. Table 9 sug-
gests a higher rate of adverse events related to prednisolone than to ciclosporin.
There was no significant difference (p = 0.175) in the number of adverse events, classified
by severity for each study arm (Table 10).
Results of routine blood laboratory, excluding the patients who had a severe adverse event,
were remarkably stable throughout the 32 weeks of the study. Seven patients had a drop in hae-
moglobin by at least 2 g/dL during their time in the study (three in the ciclosporin arm and 4 in
the prednisolone arm). These patients had been started on MDT at the beginning of the trial
and the haemoglobin drop was noted three months into the study. This is probably related to
the dapsone in the MDT. Two patients had abnormal liver function tests at week 4 which
resolved spontaneously. Renal functions (measured by serum creatinine and urea) and
Table 7. Reasons for additional prednisolone.
Reason for extra prednisolone Ciclosporin arm Prednisolone arm
T1R (skin involved) 24 16
Neuritis/ NFI 27 26
ENL 4 8
doi:10.1371/journal.pntd.0004502.t007
Fig 10. Weekly mean prednisolone per patient by treatment arm.
doi:10.1371/journal.pntd.0004502.g010
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potassium levels were stable for all patients except in the four patients who experienced a seri-
ous adverse event (see below).
Six patients recruited with T1R went on to experience ENL during the study. Details of
these patients are shown in Table 11.
All these patients had a positive BI ranging between 1 and 6, and were categorised clinically
as BB or BL. Patients experiencing both T1R and ENL can occur at this part of the spectrum
which is known to be immunologically unstable.
Table 12 lists the five serious adverse events which occurred in this study. Three were defi-
nitely attributable to prednisolone and one definitely to ciclosporin. The fifth case, a patient
diagnosed with pulmonary TB at week 22 (two weeks after stopping ciclosporin), may be
attributable to both immune-suppressive drugs.
Quality of life. Patients completed our validated SF-36 health related quality of life ques-
tionnaire in Amharic at recruitment and at the end of the study. Of the initial 35 patients in the
ciclosporin arm and the 38 in the prednisolone arm, 31 and 27 respectively completed the end
of study questionnaire. No significant difference was detected between the changes in score for
each study arm.
Table 13 shows the mean group score for each SF-36 scale at the start and at the end of the
study, divided by treatment arm. The difference in group score between baseline and end of study
is shown as the effect and the size of this effect is calculated and described. Standardised mean dif-
ferences of less than 0.30 standard deviations are small effects, 0.30–0.80 are moderate, and more
than 0.80 are large. All the scores were significantly increased (p<0.05) between the start and the
Table 8. Number of patients experiencing minor andmajor adverse events per study arm (related to ciclosporin and/ or prednisolone).
DRUG RELATED ADVERSE EVENTS Ciclosporin arm (n = 35) Prednisolone arm (n = 38)
MINOR ADVERSE EVENTS Moon Face 6 2
Acne 10 13
Fungal infections 10 8
Gastric pain 19 14
MAJOR ADVERSE EVENTS Infections 18 12
Infected ulcers 14 14
Hypertension 4 0
Diabetes mellitus 1 1
Nocturia 3 1
GI bleeding 0 2
Pulmonary tuberculosis 1 0
OTHER ADVERSE EVENTS Headache 6 2
Night sweats 3 3
Hypertrichosis 1 0
Gum hyperplasia 4 0
Depression /anxiety 3 2
Dysuria 2 0
Vomiting 4 1
Diarrhoea 3 5
GI infection—bacterial 4 1
GI infection—Giardia 3 4
GI infection—H.pylori 2 4
Blurred vision 2 3
Conjunctivitis 3 3
doi:10.1371/journal.pntd.0004502.t008
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end of the study except for the social functioning scale (SF) in both treatment arms. The changes
in score in each scale, mostly with moderate and large effect size, are shown graphically in Fig 11.
The largest score increase was in the bodily pain scale and the emotional role.
Discussion
This is a large RCT done on the treatment of leprosy T1R in Africa and the first to compare the
efficacy of ciclosporin to prednisolone. The participants were closely monitored using estab-
lished tools to measure outcomes. This is the first time that leprosy patient participant quality
of life has been assessed in a trial. We shall discuss aspects of the study design that may have
made the study more complex
We conducted a non-inferiority trial because we anticipated finding that ciclosporin and
prednisolone was not worse than prednisolone alone, in the treatment of T1R. We hoped that
the steroid sparing effect of ciclosporin may be strong enough to decrease the rate of steroid-
related side effect. A sample size of 48 patients per treatment arm was calculated with the
assumption that prednisolone, based on previous studies identified in the literature review,
leads to an improvement of about 60% in nerve function in patients with new T1R. The non-
inferiority margin of 0.25% was selected. Our study recruited a total of 73 patients, 35 in the
Table 9. Number of adverse events attributable to ciclosporin and/or prednisolone.
DRUG RELATED ADVERSE EVENT Ciclosporin related Equivocal Prednisolone related
MINOR ADVERSE EVENTS Moon Face 0 0 8
Acne 2 8 13
Fungal infections 1 5 12
Gastric pain 3 6 24
MAJOR ADVERSE EVENTS Infections 6 2 25
Infected ulcers 3 10 40
Hypertension 3 1 0
Diabetes 0 1 1
Nocturia 0 0 4
GI bleeding 0 0 2
Tuberculosis 0 1 0
OTHER ADVERSE EVENTS Headache 5 0 3
Night sweats 3 0 3
Hypertrichosis 1 0 0
Gum hyperplasia 4 0 0
Depression /anxiety 1 1 3
Dysuria 2 0 0
Vomiting 1 0 4
Diarrhoea 1 0 7
Blurred vision 2 0 3
doi:10.1371/journal.pntd.0004502.t009
Table 10. Number of adverse events classified by severity.
Ciclosporin (140) Prednisolone (128)
Severity of adverse event Mild 58 66
Moderate 70 49
Severe 12 13
doi:10.1371/journal.pntd.0004502.t010
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ciclosporin arm and 38 in the prednisolone arm. This smaller sample size reduces the power to
detect a significant difference in the study from 80% to 70%.
At the end of the 20-week intervention, both groups of patients recruited to either the ciclos-
porin and prednisolone arm or the prednisolone only arm had similar improvement rates in
Table 11. Patients in the T1R studies who experienced ENL.
Patient number Study arm Week in study at ENL occurrence R-J classiﬁcation BI at recruitment
T1RA004 Cn 6 BL 2,3,2
T1RA041 P 6 BB 1,1,1
T1RA029 Cn 10 BL 2,3,4
T1RA036 P 16 BL 6,5,5
T1RA015 P 28 BL 5,5,6
T1RA053 P 28 BL 4,3,3
doi:10.1371/journal.pntd.0004502.t011
Table 12. Serious adverse events.
Age/
Sex
Study
arm
Event
wk no
Adverse event Grad
ing
Receiving
pred
Pre-existing morbidity Causality Justiﬁcation Outcome
42/M Cn 4 Severe
headaches
3* No Severe headaches and
visual blurring.
Diagnosed with raised
intra-cranial pressure.
Deﬁnitely
related to
ciclosporin
A rare but known
side effect
Un-blinded.
Ciclosporin
stopped.
Symptoms
resolved.
Continued on
prednisolone
21/F Cn 22 Pulmonary TB 4 Yes Severe T1R
necessitating high
doses of additional
prednisolone. Had
5705mg of additional
prednisolone over 20
weeks
Deﬁnitely
related to both
drugs
Immuno-
suppression
caused by both
ciclosporin and
prednisolone
TB treatment
given for 8 months
No TB sequelae
58/M P 2 Infective
endophthalmitis
4* Yes Severe T1R –hospital
admission, noted to
have conjunctivitis and
corneal ulcer. Right eye
infection unresponsive
to topical and oral
treatment, progressed to
endophthalmitis.
Most probably
related to
prednisolone
Immuno-
suppression may
have led to
progression of
infection
Un-blinded, right
eye e-nucleation,
withdrew from
study, continued
on prednisolone at
Health Centre
54/M P 24 Death 5 Yes Severe T1R,
osteomyelitis,
septicaemia and
anaemia- all treated
week 22. On additional
prednisolone (2015mg
over 24 weeks, total
5025mg) and proton
pump inhibitor for
severe dyspepsia.
Deﬁnitely
related to
prednisolone
Developed acute
abdomen after
severe dyspepsia.
Possible
perforated gastric
ulcer and multi-
organ failure
Death
24/M P 26 Facial cellulitis 3 Yes Dental abscess–
progressed to facial
cellulitis
Most probably
related to
prednisolone
Immuno-
suppression
Recovered
Cn: ciclosporin arm; P: prednisolone arm
* Un-blinded
Grading: 1 = Mild; 2 = Moderate, 3 = Severe; 4 = Life-threatening or disabling; 5 = Death (according to National Cancer Institute adverse event grading
system–CTCAE)
doi:10.1371/journal.pntd.0004502.t012
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T1R severity as assessed by the Clinical Severity Score. Both groups of patients also showed an
improvement in clinical outcomes as assessed by the physician. In patients receiving ciclosporin
and prednisolone 100% of skin lesions recovered or improved, 75% of motor nerves improved or
recovered, and 66% of sensory nerves improved or recovered. In comparison, for patients receiv-
ing prednisolone only, we found that 94% of skin lesions had recovered, 74% of motor nerves
had improved or recovered, and 49% of sensory nerves had improved or recovered.
Skin lesions in patients on the ciclosporin and prednisolone arm flared up around weeks 6
and 8 of the study, just after the prednisolone cover was stopped at week 4. This suggests that the
therapeutic level for ciclosporin had not been reached when the prednisolone was stopped. In the
study design it was assumed that four weeks of initial prednisolone would adequately cover the
slow onset of action of ciclosporin. Several problems can be identified in retrospect with this regi-
men. The onset of action of ciclosporin is reported to be between four to eight weeks [21], so
potentially stopping the adjunctive prednisolone at week 4 was too early. Continuing predniso-
lone cover a bit longer may have prevented these early flare-ups in patients on ciclosporin.
Table 13. Mean group SF-36 scores and the effect in score difference.
Patients on Ciclosporin Arm
SF-36 variables Baseline Mean ± SD End of study Mean ± SD Effect (Difference = end of study—
baseline)
p value (paired sample t test)
Mean ± SD ES ES description
PF 50.8 ± 32.1 78.9 ± 20.3 28.1 ± 34.2 0.82 large .000
RP 31.9 ± 27.2 55.8 ± 27.2 24 ± 36.3 0.66 moderate .001
BP 20.5 ± 15.4 65.5 ± 30.7 45.1 ± 33.6 1.34 large .000
GH 32.1 ± 18.8 45.3 ± 19.6 13.2 ± 23.4 0.56 moderate .004
VT 38.1 ± 17.7 56.7 ± 20.4 18.5 ± 21.2 0.88 large .000
SF 71.0 ± 37.0 80.2 ± 29.0 9.3 ± 38.6 0.24 small .191
RE 28.0 ± 29.3 62.6 ± 32.8 34.7 ± 36.1 0.96 large .000
MH 41.1 ± 22.7 57.4 ± 22.1 16.3 ± 27.1 0.6 moderate .002
PCS 36.9 ± 7.2 47.4 ± 6.7 10.5 ± 9.8 1.06 large .000
MCS 35.1 ± 10.3 43.2 ± 11.5 8.1 ± 11.9 0.68 moderate .001
Patients on Prednisolone Arm
SF-36 variables Baseline Mean ± SD End of study Mean ± SD Effect (Difference = end of study—
baseline)
p value (paired sample t test)
Mean ± SD ES ES description
PF 54.3 ± 35.7 82.0 ± 20.1 27.8 ± 43.0 0.65 moderate .002
RP 34.3 ± 31.6 64.8 ± 20.5 30.6 ± 38.7 0.79 moderate .000
BP 28.9 ± 23.4 70.4 ± 25.6 41.5 ± 34.0 1.22 large .000
GH 39.8 ± 18.6 50.3 ± 20.0 10.6 ± 21.2 0.5 moderate .015
VT 48.8 ± 19.9 60.6 ± 19.1 11.8 ± 25.3 0.47 moderate .023
SF 74.1 ± 33.2 85.6 ± 26.6 11.6 ± 41.6 0.28 small .160
RE 33.3 ± 29.9 74.7 ± 22.2 41.4 ± 39.9 1.04 large .000
MH 45.9 ± 21.7 63.3 ± 14.9 17.4 ± 22.8 0.76 moderate .001
PCS 38.9 ± 9.8 48.6 ± 7.0 9.7 ± 12.5 0.78 moderate .000
MCS 38.0 ± 10.4 47.0 ± 6.7 9.0 ± 10.2 0.88 large .000
PF-physical functioning, RP-role physical, BP-bodily pain, GH-general health perceptions, VT-vitality, SF-social functioning, RE-role emotional, MH-
mental health, PCS-physical component summary, MCS-mental component summary
SD = standard deviation
ES = effect size = mean (effect)/ SD (baseline)
doi:10.1371/journal.pntd.0004502.t013
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Patients in the ciclosporin arm had fewer flare-ups in skin reaction signs during the follow-
up period. This may be because that the dose of prednisolone in these patients was higher in
the early follow-up period as a result of additional prednisolone given for earlier flare-ups and
therefore providing an extended protective effect. Patients in the prednisolone only group
tended to have flare-ups in skin lesions towards the end of the intervention period and in the
follow-up period as the dose of prednisolone was decreased or stopped.
In patients in both study arms, nerves reported to have been impaired for less than 6 months
showed a good improvement rate in motor function (Cn 74% and P 68%) and in sensory func-
tion (Cn 70% and P 56%). Patients who received ciclosporin and prednisolone had better
improvement in nerve function impairment than those who received prednisolone only.
Improvement in nerve function in patients on the prednisolone only arm are similar to those
reported in previous studies. In an open Bangladeshi study (n = 132), it was reported that 68%
of sensory nerves and 67% of motor nerves improved after a 16-week course of prednisolone
[8]. In the methylprednisolone trial, 70% of the patients with T1R (n = 42) who completed a 16
weeks course of prednisolone showed improved nerve function [16].
As in previous studies, an important 24 to 32% of nerves did not improve with treatment. It
may be that a proportion of these nerves with no improvement had been affected for longer
than six months or that the poor response to treatment may be due to physiological factors.
Between 36% and 46% of nerves that patients reported as having been affected for longer
than six months improved in both sensory and motor function. Evidence for the six-month
cut-off often used in deciding whether nerve function impairment should be treated with ste-
roids is based on one TRIPOD study only [22]. Patients’ accuracy of recall with regards to the
length of time the NFI has been present is problematic and may cause bias. Most of the patients
in this T1R study had not been diagnosed or not been previously seen at ALERT clinic, so that
no previous VMT/ST assessments were available for comparison and dating of NFI. It is also
difficult for patients to be exact about timing of sensory and motor NFI, especially when subtle
changes can go unnoticed.
Fig 11. Change in SF-36 scores between start and end of T1R study. PF-physical functioning, RP-role physical, BP-bodily pain, GH-general health
perceptions, VT-vitality, SF-social functioning, RE-role emotional, MH-mental health, PCS-physical component summary, MCS-mental component
summary.
doi:10.1371/journal.pntd.0004502.g011
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The timing of the first episode of T1R recurrence was significantly earlier for T1R patients
on ciclosporin and prednisolone (median 8 weeks) than those on the prednisolone only
(median 16 weeks). This reflects the earlier mentioned increase in skin reaction a week or two
after the prednisolone cover is stopped in the patients on ciclosporin. The mean and median
number of recurrences per patient was not significantly different between patients on the two
study arms. More T1R recurrence episodes occurred in the intervention period in the patients
on ciclosporin but the severity of these recurrence was not significantly different from patients
on prednisolone only. Ten patients, five in each arm of the study, had no T1R recurrence
throughout the 32 weeks in the study.
In our study, 85% of patients had a T1R recurrence. The proportion of patients with T1R
recurrence was similar for both study arms. This is a very high recurrence rate. In the Marlowe
study, patients treated with ciclosporin had a recurrence rate of 50% in skin lesions, 71% in
sensory nerve impairment and 67% in motor impairment [13]. In TRIPOD 2 [23], 27% of
patients with mild sensory impairment treated with prednisolone experienced deterioration
necessitating additional prednisolone. In the Methylprednisolone study, 45% of patients on
methylprednisolone and 50% of patients on prednisolone only required additional predniso-
lone for either skin or nerve deterioration [16]. In the Indian RCT looking at three different
prednisolone regimens, the proportions of individuals with T1R or NFI of less than three
months duration requiring additional prednisolone in the three groups was 24%, 31%, and
46% respectively. Individuals who received prednisolone for five months were significantly less
likely to require additional prednisolone [24]. It is difficult to know whether the higher rate of
recurrences in our study may be due to difference between Ethiopian and Indian or Nepalese
patients, but the Marlowe study on ciclosporin which compared two groups did find that Ethi-
opians patients had a higher rate of T1R relapse compared to Nepalese patients [13].
Significantly more additional prednisolone was required by patients in the ciclosporin arm
both during the intervention period and the full 32 weeks of the study. Mean total weekly pred-
nisolone received by patients on the ciclosporin arm was lower than that received by patients
on the prednisolone arm throughout the study except for the period week 18 to 25. In total, the
ciclosporin group received 10% less total prednisolone (p = 0.031). The magnitude of this ste-
roid sparing effect does not seem important enough to give a patient with T1R a 20-week
course of an additional immune-suppressive drug such as ciclosporin unless a large difference
in improvement of nerve function or in the rate adverse events is noted between the two treat-
ment groups.
More minor, major and serious adverse events were directly attributable to prednisolone
than to ciclosporin. Our adverse effects rates attributable to ciclosporin was similar to that in
the previous ciclosporin only trials in T1R [13] and to those reported by the drug manufactur-
ers. Six patients recruited with T1R went on to experience ENL during the study. Although it is
known that patients in the BB-BL-LL spectrum of leprosy may develop both T1R and ENL
simultaneously and/or alternatively, there is little published data on the frequency and risk fac-
tors for this phenomenon. Our data suggests that this is commoner than recognised.
This is the first time that the SF-36 Health Related Quality of Life questionnaire has been used
in a leprosy clinical trial. All the comparisons were done on group mean quality of life scores and
not on individual patient scores. There was no statistically significant difference in changes in all
scores between patients on the ciclosporin arm and those on the prednisolone arm.
All the scores were significantly increased (p<0.05) between the start of the study and the
end of the study except for the social functioning scale (SF). This means that both groups of
patients improved significantly after treatment with both treatments. Statistically significant
differences, however, do not imply that a meaningful or relevant difference has been demon-
strated for the individuals enrolled in such trials[25].
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To determine whether the observed changes in SF-36 scores were statistically and clinically
meaningful, minimal clinically important changes (MCIC) for SF-36 subscales are needed.
MCIC have not been studied in leprosy reactions so the closest we can come to defining these
is by using the published standards for minimal "clinically and socially relevant" change in
group scores as a measure of MCIC at a group level [26]. Using these criteria, all the scores of
the SF-36 scales improved by at least 5 point in the patients randomized to both treatment
arms, indicating that the improvement in quality of life was clinically and socially relevant, for
both groups with no significant difference between the two groups.
Conclusions
This study is the first double-blind RCT assessing ciclosporin, a potent immunosuppressant in
the management of T1R. All the patients with T1R treated with ciclosporin and prednisolone
or with prednisolone alone improved in all three Clinical Severity Score components. There
was no statistically significant differences between the two study arms, suggesting that treat-
ment of T1R with ciclosporin and prednisolone in non-inferior to prednisolone alone.
Recurrences of T1R were equally frequent in both treatment arms. These recurrences were
treated with additional prednisolone. The patients on the ciclosporin arm of the study received
10% less steroids than those on the prednisolone only arm during the 32 weeks of study.
This study has shown that the steroid-sparing effect of ciclosporin is limited. The pilot study
done by Marlowe in 2007 suggested that ciclosporin may be as efficient as prednisolone in the
treatment of T1R. The study designs are different and no additional prednisolone was given in
the Marlowe study for T1R or NFI flare-up; the dose of ciclosporin was increased in such cases.
In view of the fewer side effects of ciclosporin compared to prednisolone, ciclosporin could
be a useful safe alternative second-line drug for patients with T1R in whom prednisolone is not
effective, or is causing adverse events. We would recommend that ciclosporin be prescribed in
conjunction with oral prednisolone (unless the latter is contraindicated) for the initial eight
weeks. Presently a 20 week course of ciclosporin for a patient in the weight range of 40–49kg,
would cost USD 820, compared to a course of prednisolone costing USD 10.
This study has highlighted that corticosteroid treatment for T1R and NFI is sub-optimal
even when given in a standard reducing course over 20 weeks. The TENLEP multi-centre
RCTs are comparing a 32-week vs 20-week course of prednisolone for NFI [18]. This would
mean a cumulative dose of prednisolone greater than 5grams compared to 3.5grams over 20
weeks recommended by Rao [24]. The development of more prolonged treatment protocols
would require careful monitoring of adverse events and in particular the long term sequelae of
corticosteroid therapy.
This study illustrates the difficulty in switching off leprosy inflammation. Better treatment
agents for reactions and nerve damage are needed. Clinical studies in T1R should be accompa-
nied by laboratory based research to investigate the mechanisms of inflammation in T1R, iden-
tify patients at risk of recurrences and possibly identify a better agent for the treatment of T1R.
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